Christopher John Staral
Independent DirectorMr. Christopher John Staral, also known as Chris, is Independent Director of JATT II Acquisition Corp. from April 16, 2026. He is an Independent Director of JATT III Acquisition Corp. since August 25, 2026. He is the Founder, Managing Member and Chief Investment Officer of Triple Helix Investments, where he has a multidimensional background across science, public and private markets and high-performance decision-making. Mr. Staral was a Research Analyst at Goldman Sachs Group Inc., Research Division from July 2017 till January 2019. Before launching Triple Helix, Mr. Staral founded and was CIO of Allostery Investments, a specialized, low-net biotech fund known for combining deep scientific research with sentiment and technical overlays, from July 2022 to August 2025. Mr. Staral previously worked as senior analyst of Laurion Capital Management, where he played a key role in building and helping lead Laurion Capital Management’s private and long/short public biotech strategy, expanding the platform and driving investment across emerging and established therapeutic innovations. Prior to Laurion, Mr. Staral was an Investment Analyst at Mangrove Partners, focusing on high-conviction long and short opportunities within biotechnology. Mr. Staral began his finance career in sell-side equity research, first at Canaccord Genuity and later at Goldman Sachs. he ultimately gravitated to biotechnology investing because it combined his scientific interest in the complexity of human biology with the mark-to-market competition he thrived on — first as a world-class individual performer and then by building and leading elite teams in highly competitive environments. Mr. Staral received his B.A. in Chemistry and Biochemistry from Carleton College and attended the University of Minnesota Medical School in 2010.
Positions
- Company NameJATT II Acquisition Corp.Stock CodeJATTPositionIndependent Director
- Company NameJATT III Acquisition CorpStock CodeJTTTPositionIndependent Director
